|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis显示文摘 | Axel Dignass Rami Eliakim Fernando Magro Christian Maaser Yehuda Chowers Karel Geboes Gerassimos Mantzaris Walter Reinisch Jean-Frederic Colombel Severine Vermeire Simon Travis James O. Lindsay Gert Van Assche | 2012 | Journal of Crohn’s and Colitis2012，，10： | 12 |
| 2 | The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis显示文摘 | Gert Van Assche Axel Dignass Julian Panes Laurent Beaugerie John Karagiannis Mathieu Allez Thomas Ochsenkühn Tim Orchard Gerhard Rogler Edouard Louis Limas Kupcinskas Gerassimos Mantzaris Simon Travis Eduard Stange | 2009 | Journal of Crohn’s and Colitis2009，，1： | 10 |
| 3 | Endoscopic management of Crohn's strictures显示文摘Symptomatic intestinal strictures develop in more than one third of patients with Crohn's disease(CD) within 10 years of disease onset. Strictures can be inflammatory, fibrotic or mixed and result in a significant decline in quality of life, frequently requiring surgery for palliation of symptoms. Patients under the age of 40 with perianal disease are more likely to suffer from disabling ileocolonic disease thus may have a greater risk for fibrostenotic strictures. Treatment options for fibrostenotic strictures are limited to endoscopic and surgical therapy. Endoscopic balloon dilatation(EBD) appears to be a safe, less invasive and effective alternative modality to replace or defer surgery. Serious complications are rare and occur in less than 3% of procedures. For non-complex strictures without adjacent fistulizaation or perforation that are less than 5 cm in length, EBD should be considered as first-line therapy. The aim of this review is to present the current literature on the endoscopic management of small bowel and colonic strictures in CD, which includes balloon dilatation, adjuvant techniques of intralesional injection of steroids and anti-tumor necrosis factor, and metal stent insertion. Short and long-term outcomes, complications and safety of EBD will be discussed. | Talat Bessissow Jason Reinglas Achuthan Aruljothy Peter L Lakatos Gert Van Assche | 2018 | World Journal of Gastroenterology2018，24，17： | 10 |
| 4 | Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis显示文摘 | William J. Sandborn Gert van Assche Walter Reinisch Jean–Frederic Colombel Geert D’Haens Douglas C. Wolf Martina Kron Mary Beth Tighe Andreas Lazar Roopal B. Thakkar | 2012 | Gastroenterology2012，，2： | 9 |
| 5 | Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial显示文摘 | Geert D’Haens Filip Baert Gert van Assche Philip Caenepeel Philippe Vergauwe Hans Tuynman Martine De Vos Sander van Deventer Larry Stitt Allan Donner Severine Vermeire Frank J Van De Mierop Jean-Charles R Coche Janneke van der Woude Thomas Ochsenkühn Ad A | 2008 | The Lancet2008，，9613： | 5 |
| 6 | Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn’s Disease: Data From the EXTEND Trial显示文摘 | Paul Rutgeerts Gert Van Assche William J. Sandborn Douglas C. Wolf Karel Geboes Jean–Frédéric Colombel Walter Reinisch Ashish Kumar Andreas Lazar Anne Camez Kathleen G. Lomax Paul F. Pollack Geert D’Haens | 2012 | Gastroenterology2012，，5： | 4 |
| 7 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: Special situations显示文摘 | Gert Van Assche Axel Dignass Bernd Bokemeyer Silvio Danese Paolo Gionchetti Gabriele Moser Laurent Beaugerie Fernando Gomollón Winfried H?user Klaus Herrlinger Bas Oldenburg Julian Panes Francisco Portela Gerhard Rogler Jürgen Stein Herbert Tilg Simon Tra | 2012 | Journal of Crohn’s and Colitis2012，，： | 4 |
| 8 | European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease显示文摘 | J.F. Rahier S. Ben-Horin Y. Chowers C. Conlon P. De Munter G. D’Haens E. Domènech R. Eliakim A. Eser J. Frater M. Gassull M. Giladi A. Kaser M. Lémann T. Moreels A. Moschen R. Pollok W. Reinisch M. Schunter E.F. Stange H. Tilg G. Van Assche N. Viget B. Vu | 2009 | Journal of Crohn’s and Colitis2009，，2： | 3 |
| 9 | Biological Therapies for Inflammatory Bowel Diseases显示文摘 | Paul Rutgeerts Severine Vermeire Gert Van Assche | 2009 | Gastroenterology2009，，4： | 3 |
| 10 | Role of genetics in prediction of disease course and response to therapy显示文摘The clinical course of Crohn's disease and ulcerative colitis is highly variable between patients,and this has therapeutic implications.A number of clinical features have been identified,which predict a mild or more severe outcome.However,several of these are subjective and/or not persistent over time.With the progress in genetics research in inflammatory bowel disease(IBD),genetic markers are increasingly being proposed to improve stratification of patients.Genetics have the major advantage of being stable over time and not prone to subjective interpretation.Nevertheless,none of the genetic variants associated with particular outcomes have shown sufficient sensitivity or specificity to have been implemented in daily management.Along the same line of thinking,pharmacogenetics or the study of association between variability in drug response and genetic variation has also received more attention as part of the endeavor for personalized medicine.The ultimate goal in this area of medicine is to adapt medication to a patient's specific genetic background and therefore improve on efficacy and safety rates.Although pharmacogenetic studies have been performed for all classes of drugs applied in IBD,few have generated consistent findings or have been replicated.The only genetic test approved for clinical practice is thiopurine S-methyltransferase testing prior to starting treatment with thiopurine analogues.The other reported associations have suffered from lack of confirmation or still need replication efforts.Nevertheless,the importance and necessity of pharmacogenetic studies will increase further as more therapeutic classes are being developed. | Severine Vermeire Gert Van Assche Paul Rutgeerts | 2010 | World Journal of Gastroenterology2010，16，21： | 3 |
| 11 | The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Special situations显示文摘 | Gert Van Assche Axel Dignass Walter Reinisch C. Janneke van der Woude Andreas Sturm Martine De Vos Mario Guslandi Bas Oldenburg Iris Dotan Philippe Marteau Alessandro Ardizzone Daniel C. Baumgart Geert D’Haens Paolo Gionchetti Francisco Portela Boris Vuce | 2009 | Journal of Crohn’s and Colitis2009，，1： | 3 |
| 12 | The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management显示文摘 | A. Dignass G. Van Assche J.O. Lindsay M. Lémann J. S?derholm J.F. Colombel S. Danese A. D’Hoore M. Gassull F. Gomollón D.W. Hommes P. Michetti C. O’Morain T. ?resland A. Windsor E.F. Stange S.P.L. Travis | 2010 | Journal of Crohn’s and Colitis2010，，1： | 2 |
| 13 | 那他珠单抗治疗克隆病后导致进行性多灶性脑白质病 | Van Assche G. Van Ranst M. Sciot R. P. Rutgeerts 郭俊 | 2005 | 世界核心医学期刊文摘(神经病学分册)2005，0，12： | 2 |
| 14 | Anti-tumor necrosis factor treatment restores the gut barrier in Crohn’s disease显示文摘 | Peter Suenaert Veerle Bulteel Liesbeth Lemmens Maja Noman Benny Geypens Gert Van Assche Karel Geboes Jan L Ceuppens Paul Rutgeerts | 2002 | The American Journal of Gastroenterology2002，，8： | 2 |
| 15 | Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines显示文摘 | J. Panes Y. Bouhnik W. Reinisch J. Stoker S.A. Taylor D.C. Baumgart S. Danese S. Halligan B. Marincek C. Matos L. Peyrin-Biroulet J. Rimola G. Rogler G. van Assche S. Ardizzone A. Ba-Ssalamah M.A. Bali D. Bellini L. Biancone F. Castiglione R. Ehehalt R. G | 2013 | Journal of Crohn’s and Colitis2013，，7： | 2 |
| 16 | Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: A randomized, double-blind, placebo-controlled trial显示文摘 | Paul Rutgeerts Gert van Assche Séverine Vermeire Geert D’Haens Filip Baert Maja Noman Isolde Aerden Gert de Hertogh Karel Geboes Martin Hiele Andre D’Hoore Freddy Penninckx | 2005 | Gastroenterology2005，，4： | 2 |
| 17 | Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn’s Disease显示文摘 | Matthias Jürgens Jestinah M. Mahachie John Isabelle Cleynen Fabian Schnitzler Herma Fidder Wouter van Moerkercke Vera Ballet Maja Noman Ilse Hoffman Gert van Assche Paul J. Rutgeerts Kristel van Steen Severine Vermeire | 2011 | Clinical Gastroenterology and Hepatology2011，，5： | 2 |
| 18 | Classification of inflammatory bowel disease: the old and the new显示文摘 | Severine Vermeire Gert Van Assche Paul Rutgeerts | 2012 | Current Opinion in Gastroenterology2012，，4： | 2 |
| 19 | Sa1922 Pilot Study on the Safety and Efficacy of Faecal Microbiota Transplantation in Refractory Crohn’s Disease显示文摘 | Severine Vermeire Marie Joossens Kristin Verbeke Falk Hildebrand Kathleen Machiels Karolien Van den Broeck Gert Van Assche Paul J. Rutgeerts Jeroen Raes | 2012 | Gastroenterology2012，，5： | 2 |
| 20 | Review article: anti‐adhesion therapies for inflammatory bowel disease显示文摘 | T. Lobatón S. Vermeire G. Assche P. Rutgeerts | 2014 | Aliment Pharmacol Ther2014，，6： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员